Persistent Salmonella enterica serovar Typhimurium infection increases the susceptibility of mice to develop intestinal inflammation
Cargando...
Archivos
Fecha
2018-05
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
Frontiers Media
Nombre de Curso
Licencia CC
Licencia CC
Resumen
Chronic intestinal inflammations are triggered by genetic and environmental components. However, it remains unclear how specific changes in the microbiota, host immunity, or pathogen exposure could promote the onset and exacerbation of these diseases. Here, we evaluated whether Salmonella enterica serovar Typhimurium (S. Typhimurium) infection increases the susceptibility to develop intestinal inflammation in mice. Two mouse models were used to evaluate the impact of S. Typhimurium infection: the chemical induction of colitis by dextran sulfate sodium (DSS) and interleukin (IL)-10-/- mice, which develop spontaneous intestinal inflammation. We observed that S. Typhimurium infection makes DSS-treated and IL-10-/- mice more susceptible to develop intestinal inflammation. Importantly, this increased susceptibility is associated to the ability of S. Typhimurium to persist in liver and spleen of infected mice, which depends on the virulence proteins secreted by Salmonella Pathogenicity Island 2-encoded type three secretion system (TTSS-2). Although immunization with a live attenuated vaccine resulted in a moderate reduction of the IL-10-/- mice susceptibility to develop intestinal inflammation due to previous S. Typhimurium infection, it did not prevent bacterial persistence. Our results suggest that persistent S. Typhimurium infection may increase the susceptibility of mice to develop inflammation in the intestine, which could be associated with virulence proteins secreted by TTSS-2. © 2018 Schultz, Salazar, Paduro, Pardo-Roa, Pizarro, Salazar-Echegarai, Torres, Riedel, Kalergis, álvarez-Lobos and Bueno.
Notas
Indexación: Scopus.
This study was supported by grants 'Fondo Nacional de Ciencia y Tecnología de Chile' (FONDECYT) (# 1100971, 1110604, 1140010, 1150862, 1161525, 1131012, and 1170964); Millenium Institute on Immunology and Immunotherapy P09/016-F from the Iniciativa Científica Milenio, Ministry of Economy, Chilean Government; Proyecto Puente P 1715/2017, Dirección de Investigación, Vicerrectoría de Investigación, Pontificia Universidad Católica de Chile. BS and CP-R are supported by the Comisión Nacional de Investigación Científica y Tecnológica (CONICYT).
This study was supported by grants 'Fondo Nacional de Ciencia y Tecnología de Chile' (FONDECYT) (# 1100971, 1110604, 1140010, 1150862, 1161525, 1131012, and 1170964); Millenium Institute on Immunology and Immunotherapy P09/016-F from the Iniciativa Científica Milenio, Ministry of Economy, Chilean Government; Proyecto Puente P 1715/2017, Dirección de Investigación, Vicerrectoría de Investigación, Pontificia Universidad Católica de Chile. BS and CP-R are supported by the Comisión Nacional de Investigación Científica y Tecnológica (CONICYT).
Palabras clave
Colitis, Dextran sulfate sodium, Inflammatory bowel disease, Interleukin-10, Persistence, Salmonella enterica serovar, Typhimurium
Citación
Frontiers in Immunology, 9(MAY), art. no. 1166.